Great Point Partners LLC Biocryst Pharmaceuticals Inc Transaction History

Great Point Partners LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$2.91 - $9.15 $17.3 Million - $54.5 Million	-5,955,762 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$7.38 - $9.72 $12.3 Million - $16.2 Million	-1,666,494 Reduced 21.86%	5,955,762 $48.5 Million
Q4 2018 Feb 15, 2019	SELL	$6.51 - $9.6 $2.32 Million - $3.42 Million	-356,019 Reduced 4.46%	7,622,256 $61.5 Million
Q3 2018 Nov 14, 2018	BUY	$5.52 - $7.99 $2.76 Million - $4 Million	500,000 Added 6.69%	7,978,275 $60.9 Million
Q1 2018 May 14, 2018	BUY	$4.35 - $5.82 $11.9 Million - $15.9 Million	2,726,392 Added 57.37%	7,478,275 $0
Q4 2017 Feb 14, 2018	BUY	$4.16 - $5.33 $13 Million - $16.6 Million	3,114,551 Added 190.22%	4,751,883 $23.3 Million
Q3 2017 Nov 14, 2017	BUY	$4.1 - $5.97 $6.71 Million - $9.77 Million	1,637,332	1,637,332 $8.58 Million

279

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Great Point Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Great Point Partners LLC with notifications on news.